Samuel Anyanwu

Appearances

UPADACITINIB IMPROVES ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN’S DISEASE IRRESPECTIVE OF PREVIOUS FAILURE TO RESPOND TO BIOLOGICS OR CONVENTIONAL THERAPIES
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Brian Feagan
Western University
Speakers
Sara Horst
Gerald Dryden
James Lindsay
Barts & The London School of Medicine and Dentistry
Marc Ferrante
Elena Dubcenco
Ana Lacerda
Sharanya Ford
Samuel Anyanwu
Qian Zhou
Jianzhong Liu
Minhu Chen
Stefan Schreiber